Bessemer Group’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.34M | Sell |
1,728
-2,653
| -61% | -$2.03M | ﹤0.01% | 896 |
|
|
2025
Q4 | $3.38M | Buy |
4,381
+1,710
| +64% | +$1.16M | 0.01% | 576 |
|
|
2025
Q3 | $1.5M | Buy |
2,671
+1,554
| +139% | +$879K | ﹤0.01% | 553 |
|
|
2025
Q2 | $586K | Sell |
1,117
-101
| -8% | -$56.4K | ﹤0.01% | 775 |
|
|
2025
Q1 | $772K | Sell |
1,218
-3,860
| -76% | -$2.65M | ﹤0.01% | 774 |
|
|
2024
Q4 | $3.62M | Sell |
5,078
-174
| -3% | -$146K | 0.01% | 497 |
|
|
2024
Q3 | $5.52M | Buy |
5,252
+159
| +3% | +$177K | 0.01% | 402 |
|
|
2024
Q2 | $5.35M | Buy |
5,093
+18
| +0.4% | +$17.4K | 0.01% | 361 |
|
|
2024
Q1 | $4.89M | Buy |
5,075
+2,624
| +107% | +$2.5M | 0.01% | 385 |
|
|
2023
Q4 | $2.15M | Sell |
2,451
-323
| -12% | -$266K | ﹤0.01% | 469 |
|
|
2023
Q3 | $2.28M | Sell |
2,774
-65
| -2% | -$51.1K | 0.01% | 453 |
|
|
2023
Q2 | $2.04M | Buy |
2,839
+293
| +12% | +$226K | ﹤0.01% | 478 |
|
|
2023
Q1 | $2.09M | Sell |
2,546
-420
| -14% | -$317K | 0.01% | 444 |
|
|
2022
Q4 | $2.14M | Buy |
2,966
+35
| +1% | +$25.8K | 0.01% | 436 |
|
|
2022
Q3 | $2.02M | Buy |
2,931
+254
| +9% | +$160K | 0.01% | 446 |
|
|
2022
Q2 | $1.58M | Buy |
2,677
+41
| +2% | +$26.7K | ﹤0.01% | 485 |
|
|
2022
Q1 | $1.84M | Buy |
2,636
+435
| +20% | +$275K | ﹤0.01% | 373 |
|
|
2021
Q4 | $1.39M | Buy |
2,201
+704
| +47% | +$433K | ﹤0.01% | 406 |
|
|
2021
Q3 | $905K | Buy |
1,497
+45
| +3% | +$27.9K | ﹤0.01% | 436 |
|
|
2021
Q2 | $811K | Buy |
1,452
+54
| +4% | +$27.4K | ﹤0.01% | 460 |
|
|
2021
Q1 | $662K | Buy |
1,398
+229
| +20% | +$111K | ﹤0.01% | 484 |
|
|
2020
Q4 | $565K | Sell |
1,169
-106,817
| -99% | -$57.7M | ﹤0.01% | 499 |
|
|
2020
Q3 | $60.4M | Buy |
107,986
+17,341
| +19% | +$10.5M | 0.18% | 137 |
|
|
2020
Q2 | $56.5M | Buy |
90,645
+2,558
| +3% | +$1.45M | 0.18% | 129 |
|
|
2020
Q1 | $43M | Buy |
88,087
+135
| +0.2% | +$55.7K | 0.17% | 138 |
|
|
2019
Q4 | $33M | Sell |
87,952
-26,983
| -23% | -$9.08M | 0.11% | 171 |
|
|
2019
Q3 | $31.9M | Sell |
114,935
-8,497
| -7% | -$2.51M | 0.11% | 167 |
|
|
2019
Q2 | $38.6M | Buy |
123,432
+122,811
| +19,776% | +$40.9M | 0.13% | 162 |
|
|
2019
Q1 | $255K | Buy |
621
+126
| +25% | +$51.9K | ﹤0.01% | 945 |
|
|
2018
Q4 | $184K | Buy |
495
+94
| +23% | +$34.4K | ﹤0.01% | 999 |
|
|
2018
Q3 | $163K | Sell |
401
-6
| -1% | -$2.28K | ﹤0.01% | 1030 |
|
|
2018
Q2 | $140K | Sell |
407
-474
| -54% | -$148K | ﹤0.01% | 1048 |
|
|
2018
Q1 | $304K | Buy |
881
+508
| +136% | +$177K | ﹤0.01% | 921 |
|
|
2017
Q4 | $141K | Sell |
373
-290
| -44% | -$117K | ﹤0.01% | 1083 |
|
|
2017
Q3 | $297K | Buy |
663
+600
| +952% | +$286K | ﹤0.01% | 980 |
|
|
2017
Q2 | $31K | Buy |
63
+37
| +142% | +$16.2K | ﹤0.01% | 1396 |
|
|
2017
Q1 | $10K | Sell |
26
-113
| -81% | -$41.9K | ﹤0.01% | 1535 |
|
|
2016
Q4 | $51K | Sell |
139
-17
| -11% | -$6.46K | ﹤0.01% | 1343 |
|
|
2016
Q3 | $63K | Sell |
156
-253
| -62% | -$101K | ﹤0.01% | 1177 |
|
|
2016
Q2 | $143K | Sell |
409
-139
| -25% | -$53.5K | ﹤0.01% | 716 |
|
|
2016
Q1 | $198K | Buy |
548
+171
| +45% | +$70.5K | ﹤0.01% | 675 |
|
|
2015
Q4 | $205K | Buy |
377
+127
| +51% | +$68.8K | ﹤0.01% | 731 |
|
|
2015
Q3 | $116K | Buy |
250
+48
| +24% | +$25.8K | ﹤0.01% | 815 |
|
|
2015
Q2 | $103K | Buy |
202
+174
| +621% | +$84.9K | ﹤0.01% | 838 |
|
|
2015
Q1 | $13K | Buy |
+28
| New | +$11.9K | ﹤0.01% | 1188 |
|
Other funds holding REGN
VCM
N
Bessemer Group's REGN Position: Q1 2026 in Review
Bessemer Group reduced its Regeneron Pharmaceuticals (REGN) stake by 61% in Q1 2026, selling an estimated $2.03M and leaving 1,728 shares worth $1.34M. The position accounts for ﹤0.01% of the portfolio, ranked #896.
Bessemer Group first reported a position in REGN in Q1 2015 and has held it in 45 quarters since. The position peaked at $60.4M in Q3 2020. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Bessemer Group held 1,728 shares of Regeneron Pharmaceuticals worth $1.34M as of Q1 2026.
- Bessemer Group sold 2,653 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $2.03M.
- Regeneron Pharmaceuticals made up ﹤0.01% of Bessemer Group's portfolio in Q1 2026, its #896 holding.
- Bessemer Group first reported a position in Regeneron Pharmaceuticals in Q1 2015 and has held it in 45 quarters since.
- Bessemer Group's Regeneron Pharmaceuticals position peaked at $60.4M in Q3 2020.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.